Inflammatory bowel diseases: a new wave of therapy

被引：2

作者：

Murthy, S ^{[1
]}

Flanigan, A ^{[1
]}

Osborne, BJ ^{[1
]}

Murthy, NS ^{[1
]}

机构：

[1] Allegheny Univ Hlth Sci, Div Gastroenterol & Hepatol, Krancer Ctr IBD Res, Philadelphia, PA 19102 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 1998年 / 8卷 / 07期

关键词：

adhesion molecule inhibition; arachidonic acid inhibitors; chemokine inhibitors; Crohn's disease; cytokine inhibitors; elastase inhibitors; growth factors; immunosuppressives; inflammatory bowel disease; nitric oxide inhibitors; nuclear factor kappa B inhibitors; superoxide dismutase mimics; tachykinin antagonists; tobacco products; ulcerative colitis;

D O I：

10.1517/13543776.8.7.785

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This review focuses on recent advances in the pathogenesis of inflammatory bowel diseases (IBDs) and current developments in claimed patents for the management of these diseases. These are developed in the hope of replacing conventional corticosteroids, 5-aminosalicylic acids (5-ASA) and immunosuppressants which have been the mainstay of therapy for decades. These patents represent a change in direction to more specific therapies to block a host of inflammatory mediators, either at their synthesis level or blocking binding to their designated receptors. The changes also represent a shift from synthetic inhibitors to biologicals for which the in vivo efficacy and side-effects need to be evaluated. These advancements represent a new wave of therapy to treat these debilitating diseases.

引用

页码：785 / 818

页数：34

共 145 条

[1] ADHESION MOLECULES AND INFLAMMATORY INJURY [J].